The products include OP-1 Implant, OP-1 Putty, Opgenra and Osigraft. The transaction also includes the sale of the manufacturing facility in Lebanon, N.H.
Read the Stryker release on the transaction.
Read other coverage on Stryker:
– Stryker Acquires Boston Scientific Corp.’s Neurovascular Business for $1.5B
– Stryker’s David Veino: In Support of Vertebroplasty
– Stryker Receives Two Subpoenas for Device Marketing
